This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Meijboom M, Botteman MF, Kaura S.Cost effectiveness of zoledronic acid for the prevention of skeletal related events in prostate cancer patients with bone metastases in France and Germany. 24th Annual Congress of the European Association of Urology: 132 abstr. 47, 18 Mar 2009
Botteman MF, Stephens J, Foley I, Kaura S.Cost effectiveness of zoledronic acid in the prevention of skeletal related events in renal cell carcinoma patients with bone metastases: an exploratory analysis for France. 24th Annual Congress of the European Association of Urology: 157 abstr. 145, 18 Mar 2009
Rights and permissions
About this article
Cite this article
Zoledronic acid to prevent SREs in prostate, renal cancer cost effective. Pharmacoecon. Outcomes News 578, 9 (2009). https://doi.org/10.2165/00151234-200905780-00019
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905780-00019